Doctor profile · Federal record
Dr. Gustavo Meyreles-Chaljub, M.D.
Endocrinology, Diabetes & Metabolism Physician (CMS: Endocrinology) · Endocrinology, Diabetes & Metabolism Physician · Tampa, FL
- NPI 1700325479
- Accepts Medicare
- 7 yrs in practice
- Licensed in 2 states
- Male
- Group practice
- No sanctions
Practice & contact
Operates at 3 locations .
- Primary practice
-
602 S Audubon Ave Ste A
Tampa, FL 336094217
(813) 931-2424 - Additional location
-
1175 Cook RD Ste 145
Orangeburg, SC 291188235
(803) 395-3891 - Additional location
-
17 Davis Blvd Ste 308
Tampa, FL 336063438
(813) 974-2460
fax (813) 974-2580
Credentials & registration
- NPI registered
- February 2017 — 9 yrs on file
- Profile last updated
- January 17, 2024
- Year of graduation
- 2019 — 7 yrs since
- Specialty taxonomy
- 207RE0101X — NUCC code
- State licenses (2)
- South Carolina #83083 · Florida #ME164432
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1700325479. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
3,370
Distinct HCPCS
10
Medicare allowed
$143,994
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
J0897 |
Injection, denosumab, 1 mg | 2,400 | 28 | $23 | |
99215 |
Established patient office or other outpatient visit, 40-54 minutes | 225 | 131 | $168 | |
99214 |
Established patient office or other outpatient visit, 30-39 minutes | 217 | 127 | $120 | |
83036 |
Hemoglobin a1c level | 179 | 104 | $10 | |
95251 |
Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 114 | 60 | $33 | |
96372 |
Injection of drug or substance under skin or into muscle | 106 | 38 | $13 | |
99205 |
New patient office or other outpatient visit, 60-74 minutes | 54 | 54 | $207 | |
G2212 |
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | 32 | 17 | $30 | |
95250 |
Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 29 | 27 | $128 | |
99204 |
New patient office or other outpatient visit, 45-59 minutes | 14 | 14 | $147 |
In context: peer comparison
Among 15 peers in this city , average services per provider: 175. This provider delivers 19× the peer median.Open Payments
Industry payments received
All-time total
$1,447
Transactions
49
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Amgen Inc. | 11 | $304.17 | |
| Novo Nordisk Inc | 6 | $128.99 | |
| Tandem Diabetes Care, Inc. | 5 | $128.63 | |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $112.21 | |
| Insulet Corporation | 5 | $108.15 | |
| SANOFI-AVENTIS U.S. LLC | 3 | $81.48 | |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $75.32 | |
| Medtronic, Inc. | 2 | $54.71 | |
| Abbott Laboratories | 1 | $49.95 | |
| ABBVIE INC. | 2 | $49.50 | |
| Xeris Pharmaceuticals, Inc. | 2 | $41.71 | |
| Lilly USA, LLC | 2 | $38.71 | |
| Mannkind Corporation | 1 | $32.87 | |
| WATERMARK MEDICAL, INC. | 1 | $28.25 | |
| Madrigal Pharmaceuticals | 1 | $27.44 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
2,317
Patients
733
Total drug cost
$1,705,624
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Ozempic (Semaglutide) | Brand | 409 | 108 | $669,191 |
| Levothyroxine Sodium | Generic | 279 | 81 | $4,664 |
| Metformin Hcl Er (Metformin Hcl) | Brand | 193 | 70 | $5,093 |
| Farxiga (Dapagliflozin Propanediol) | Brand | 188 | 51 | $190,408 |
| Trulicity (Dulaglutide) | Brand | 149 | 38 | $250,650 |
| Methimazole | Generic | 143 | 42 | $2,289 |
| Lantus Solostar (Insulin Glargine,hum.Rec.Anlog) | Brand | 135 | 52 | $72,966 |
| Humalog Kwikpen U-100 (Insulin Lispro) | Brand | 125 | 49 | $119,793 |
| Toujeo Solostar (Insulin Glargine,hum.Rec.Anlog) | Brand | 118 | 44 | $83,609 |
| Glipizide | Generic | 103 | 29 | $1,618 |
Hospital affiliations
Frequently asked questions
What is Dr. Gustavo Meyreles-Chaljub's medical specialty?
Dr. Gustavo Meyreles-Chaljub practices Endocrinology, Diabetes & Metabolism Physician in Tampa, FL.
Where does Dr. Gustavo Meyreles-Chaljub practice?
Dr. Gustavo Meyreles-Chaljub practices at 602 S Audubon Ave Ste A, Tampa, FL 336094217. Office phone: 8139312424.
What is Dr. Gustavo Meyreles-Chaljub's NPI?
Dr. Gustavo Meyreles-Chaljub's National Provider Identifier (NPI) is 1700325479, issued by NPPES.
Does Dr. Gustavo Meyreles-Chaljub accept Medicare assignment?
Yes. Dr. Gustavo Meyreles-Chaljub accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Gustavo Meyreles-Chaljub commonly perform?
Top Medicare-reported procedures in 2023: Injection, denosumab, 1 mg (HCPCS J0897); Established patient office or other outpatient visit (HCPCS 99215); Established patient office or other outpatient visit (HCPCS 99214). Source: CMS Medicare Physician & Other Practitioners file.